Viatris announced Q3 2026 results with $3.75 billion in revenue, a $325 million U.S. GAAP net loss, and $1.20 billion adjusted EBITDA. Despite supply constraints and competition, strong sales in developed markets and Greater China supported stable revenue. The company received U.S. approval for RYZUMVI and Japan approval for WAKIX, launched Gwyn Lo in the U.S., and plans to acquire Pacira BioSciences by November, aiming to boost innovative medicines. Viatris raised its 2026 financial guidance midpoints and returned $717 million to shareholders year-to-date, signaling confidence in growth and operational momentum.
As of Nov 05, 2026 19:01 WIB, Viatris (VTRS) trades at USD 19.30 on Pluang, showing a modest 0.42% increase for the day. Its market cap stands at $22.11 billion, with a dividend yield of 2.49%, reflecting a steady position in the health sector. Compared to its 52-week range, this price suggests relative stability amid the company's recent financial updates and strategic moves.
